X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): APL-1702
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Cevira
Highest Development Status: Phase III Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 11, 2020
Details:
APL-1702 (Cevira ® ) is a photodynamic drug device combination product. Based on the principle of photodynamics, it combines a photosensitizer with a specific wavelength of light activation to produce a therapeutic effect.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Photodynamic drug
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Cevira
Highest Development Status: Phase III Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 08, 2020
Details:
Asieris has received Clinical Trial Approval from China NMPA for the global, multi-centered Phase III clinical trial of its photodynamic drug-device combination product Cevira®, which is being developed for the non-surgical treatment of high-grade cervical dysplasia.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
